The story of Robert Duggan, who turned to biotech investing after the tragic loss of his son to cancer, is garnering significant attention. As reported by Forbes, Duggan, born in 1944, is now 80 years old and boasts a net worth of $16 billion.
The Wall Street Journal featured his journey in an article titled “How a Surfer Who Never Finished College Became a Biotech Billionaire.” Once an ordinary baker and avid surfer, Duggan found joy in the ocean and baking despite not holding a college degree. However, everything changed in 2004 when his son died of cancer at just 26. This profound loss prompted Duggan to seek ways to combat diseases and possibly save lives.
He began investing in PharmaCyclics, a pharmaceutical company developing new treatments for his son’s illness. Using savings from his baking business, Duggan invested in the company, which, while it didn’t develop a cancer drug, successfully created a treatment for leukemia—a “blockbuster” that significantly increased his wealth.
Duggan continued to pursue biotech investments and became CEO of Summit Therapeutics in 2022. Under his leadership, the company made strides in developing new drugs for lung cancer, resulting in a remarkable 1,000% increase in stock price over the previous year. The WSJ noted that this success surprised many, as Duggan was already a billionaire.
In an interview with the WSJ, Duggan reflected on his early career, noting that people often laugh when he mentions his days as a baker and surfing. He explained that even during that time, he aimed to bake the best chocolate cookies, striving for the perfect chewy texture, a mindset he believes has significantly contributed to his success.
While the new drugs still require extensive safety testing, the WSJ emphasized Duggan’s determination as a testament to how an ordinary individual can thrive in the biotech industry. His story challenges the notion that impressive educational credentials and complex jargon dominate the field, highlighting that a genuine desire to learn and innovate is key.
